Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets the TREM-1 pathway to control unbalanced inflammatory responses.
Inotrem identified the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of TREM-1 pathway.
Inotrem conducts clinical programs using nangibotide for the treatment of acute inflammatory diseases such as septic shock and COVID-19. It also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
INOTREM SA is a biopharmaceutical company discovering and developing first-in-class immunotherapies for the treatment of inflammatory diseases.
A first clinical trial to assess the safety, tolerability and pharmacokinetics of MOTREM in healthy volunteers is currently ongoing.
Paris, July 12th. 2021. Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in
Paris, July 12th. 2021. Inotrem S.A., a biotechnology company specializing in the development of immunotherapies targeting the TREM-1 pathway, announces that it has obtained authorization to pursue the clinical development of nangibotide up to registration in
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Inotrem 2018 – Legal notices
INOTREM S.A | 114 rue la Boétie 75008 PARIS
Inotrem 2018 – Legal notices